Specifically, MAF794 cell line, derived from a paediatric ganglioglioma carrying BRAF V600E mutation, shows higher autophagy levels when compared to BT16 BRAF wild-type cells; moreover, autophagy inhibition—either pharmacologic or genetic—leads to cell viability reduction. This evidence concerns the gene BRAF and ganglioglioma.